similars The vice president of Laboratorios Beta discusses the factors of why his organization is on the way to consolidating its different business lines and becoming a pure pharmaceutical company. 2014 marks the 74th anniversary of Laboratorios Beta. To what extent is the company today still the same company…
Biosimilars Dr. Liu, President and CEO of EirGenix, talks about why he sees Taiwan as the ideal market for a CDMO like Eirgenix, why he believes that despite the skepticism, biosimilars will be able to overcome the initial barriers, and where he sees EiGenix in the next several years. What has…
Biosimilars Audrey Tseng, Deputy Chairman of PwC Taiwan with PwC Partners Lily Wong and Andy Chang, delve into factors behind the booming pharma and biotech industry in Taiwan, how to prevent a bubble burst, and the crucial next steps in maintaining the momentum to continue growth within the industry. Please start…
Biosimilars Jaw-Jou Kang, former Director General of Taiwan Food & Drug Administration (TFDA) discusses the key successes the company has had since 2010, where it is looking to in the future and how a relationship with China would be mutually beneficial for both countries. Since Taiwan Food & Drug Administration’s founding…
Biosimilars Jim Keon, Preisdent of CGPA, discusses the cost-saving benefits that generic drugs have offered Canada, and offers his insights into Canada’s intellectual property regime and the challenges of pricing in Canada. As a privileged witness to the evolution of the Canadian generic industry, what have been some of the defining…
See our Cookie Privacy Policy Here
